mutations provided the fact that, as stated beneath, CLL therapy relies within the presence or absence of such mutations. The existing consensus is, other than clonal mutations, subclonal mutations that has a variant allelic frequency ranging from 5 to ten% (and thus beneath the brink of detection by regular molecular procedures) is also reported,